Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
IC

NYSE · ICUI

ICU Medical, Inc.

Healthcare · Medical - Instruments & Supplies

$163.78

Down-$4.87 (-2.89%)

Updated Oct 31, 2026, 5:08 PM

SID Score

5.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.63B
P/E ratio
-624.25
Dividend yield
0.00%
52-week range
$113.37 – $192.85
Volume
216.56K
Avg. volume
272.38K

Price performance · ICUI

ICUI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ICUI closed at $163.78 after 21 trading sessions, up 2.76% for the selected period.

Last close
$163.78
Period change
+2.76%
Period low
$156.03
Period high
$168.65
Daily close
View OHLC price history
ICUI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$169.64$170.00$163.145$163.78216.56K
Oct 29, 2026$168.85$169.65$166.1634$168.65202.5K
Oct 28, 2026$161.63$166.645$157.63$166.39156.45K
Oct 27, 2026$166.41$166.41$162.97$163.20323.15K
Oct 26, 2026$166.42$168.48$162.88$165.96155.39K
Oct 23, 2026$166.92$167.945$160.8859$166.62272.32K
Oct 22, 2026$160.98$168.62$160.67$168.33241.77K
Oct 21, 2026$159.52$162.20$159.02$160.84219.98K
Oct 20, 2026$161.60$164.00$160.57$161.08160.2K
Oct 19, 2026$163.00$164.15$160.215$161.24153.81K
Oct 16, 2026$167.30$167.80$162.51$162.99221.68K
Oct 15, 2026$164.10$167.725$164.10$167.23239.47K
Oct 14, 2026$162.20$163.865$161.635$162.69258.44K
Oct 13, 2026$165.16$167.05$162.99$163.23236.79K
Oct 12, 2026$159.73$164.40$159.50$163.91201.35K
Oct 9, 2026$157.46$160.47$157.46$160.32146K
Oct 8, 2026$154.81$157.50$153.33$157.18220.61K
Oct 7, 2026$157.89$160.50$155.54$156.03214.62K
Oct 6, 2026$162.55$162.55$157.65$159.73238.61K
Oct 5, 2026$159.35$162.81$157.80$161.40211.45K
Oct 2, 2026$158.78$161.325$157.15$159.38227.67K

Latest ICUI news

The latest Smart Investors Daily articles mentioning ICUI.

Stock researchCompany · Overview

ICUI research

Overview

Company profile and research snapshot.

Company profile

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$163.00
Implied upside
—
Analysts
—
ICUI recent ratings
DateFirmRatingTarget
Aug 7, 2026Piper SandlerOverweight—
Aug 7, 2026BTIGBuy—
Aug 7, 2026NeedhamBuy—
Jul 21, 2026KeybancOverweight—
Jun 15, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call

SAN CLEMENTE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2026 earnings release and conference call. The Company will release its third quarter 2026 results on Thursday, November 5, 2026, at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursda

Yahoo · Oct 7, 2026

Is ICU Medical (ICUI) Undervalued After Two FDA Class II Recalls?

ICU Medical (ICUI) is back in focus after two FDA Class II recalls: one for CADD Yellow Medication Cassette Reservoirs and another for Plum administration sets, both tied to device integrity issues worldwide. ICU Medical’s share price has slipped in the very short term, with a 1-day share price return of 1.03% lower and a 7-day move down 2.27%. However, the 90-day share price return of 5.16% and year to date gain of 15.30% suggest momentum has built over recent months even as these FDA Class...

Yahoo · Sep 19, 2026

ICU Medical (ICUI) Stock May Be 26% Undervalued On Cash Flow

ICU Medical has climbed back into positive territory over the past year, yet its longer track record remains mixed, which puts fresh attention on what the current share price asks you to pay for its future cash flows. With the stock closing at US$152.65 most recently, the key issue is whether that tag lines up with what the business can realistically generate over time. Over the past 5 years, ICU Medical shares have fallen 37.1%, which makes the current valuation question more about the...

Yahoo · Sep 18, 2026

Vascular Access Device Market by Type, Route of Insertion, Application, End User - Global Forecast to 2031

The global vascular access device market is projected to grow from USD 6.27 billion in 2026 to USD 8.68 billion by 2031, at a 6.7% CAGR. Growth is driven by rising cancer, cardiovascular and kidney disease cases, increased IV therapies and advances in safety-engineered, antimicrobial and ultrasound-guided devices. Peripheral devices and drug administration will see strong growth, while clinics and ambulatory care centers gain adoption. Asia Pacific is forecast to record the highest CAGR. Key pla

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By